JN International Medical Corporation Medical Corporation

Research & Development of Vaccines

Home About us Patents Vaccines Diagnostics Clinical Trials Facilities Investment Global Health Contact us

A TRIBUTE TO OUR ATTORNEY: Mr. Jeffery Harold Bush, passed away. on August 16, 2007, about 15 years, serving as our Corporate attorney.

About his sayings - each year, millions of people in developing countries either die or suffer from diseases that could be prevented by current vaccines. JN International Medical Corporation investing to accelerate the development and introduction of appropriate and affordable vaccines in impoverished countries. I suppose this cannot be done by JN alone and may play a part of it.?- Jeffery H. Bush..

Meningitis Vaccines

The Vaccine is almost ready for the market in couple years. We are making every effort to meet the requirements of regulatory and at the same time researching for scale-up to create affordability for developing countries

Meningococcal meningitis vaccine

Meningococcal meningitis A,C,Y,W-135 Polysaccharide Vaccines

NmVac-4 A/C/Y/W-135 ™ Polysaccharide Vaccine

Meningococcal polysaccharide vaccine

Phase 3 trials of Meningococcal meningitis A, C, Y, W-135 plain polysaccharide vaccine trials were successfully completed in sub-Sharon Africa (Niger and Burkina Faso) using 750 people. Immunogenicity and protection described in the product insert.

Meningococcal A.C.Y.W-135 Diphtheria vaccine

NmVac-4 A/C/Y/W-135 DT™ Polysaccharide DT Vaccine

Meningococcal groups A C Y and W-135 DT conjugate vaccines were developed using a genetically detoxified Diphtheria Toxoid as the protein carrier

Phase 3 trials is successfully completed and approved by Ministry of Health of Côte d'Ivoire in North Ivory Coast using 100 sero-negative male and female volunteers. Protective sero-conversion recorded in 98% individuals tested by Pasture Research Institute.

Diphtheria Toxoid was chosen for low-cost vaccine production. The vaccine had a tremendous impact on the incidence of the disease, resulting in a more than 90% decrease in the number of deaths and clinical cases, and a 66% decrease in asymptomatic carriage (cf. WHO) in sub-Saharan Africa.

Vaccine Discovery

JN's Research Facilities are in the discovery, development, and clinical evaluation of vaccine products for vaccine-preventable disorders and diseases.

Stroke and Neurological disorders

Phase I Clinical Trial

Stroke Vaccine

This first stage of stroke clinical trials is designed to gain basic safety and pharmacologic information. Single or multiple conservative doses of the drug will be administered to volunteers. Analysis of these studies allow JN to assess the drug’s mechanism of action in humans, pharmacology, pharmacokinetics, side effects of various doses, safe dosage range, and the optimal route of administration. Animal model experiments using pigs were successfully proved that the vaccine can protect and cure the Endothelia-1 induced MCA occlusion in experimental pigs with no side effects or damage to vital organs. Memory related aspects in vaccinated compared to untreated showed "Hippocampal Retrieval of Food-Flavor Memory" and this parameter is proved to be successful, the project moves to phase-1 human trials.

Hepatitis C DNA / Protein Vaccine

The current invention draws scope of newer methodologies in the development of vaccine against Hepatitis C virus genotype-1a and b on the basis of phylogenetic analysis of nucleotide sequences of NS3/NS4a genes of multiple genotypes and subtypes of Flaviviruses. The immunization of r-NS3/NS4a protein or DNA induced humoral and cell mediated protective immune response against Hepatitis C viruses 1a and 1b in mouse models and not sure how it works for human? unless we go for phase -1 human trials.

Laboratory Phase

Herpes

Tuberculosis

Patented Technology

View Filed Patents

Accessing the web pages or using these results in any manner whatsoever, you agree to be bound by the foregoing restrictions.